<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">LUP</journal-id>
<journal-id journal-id-type="hwp">splup</journal-id>
<journal-id journal-id-type="nlm-ta">Lupus</journal-id>
<journal-title>Lupus</journal-title>
<issn pub-type="ppub">0961-2033</issn>
<issn pub-type="epub">1477-0962</issn>
<publisher>
<publisher-name>SAGE Publications</publisher-name>
<publisher-loc>Sage UK: London, England</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.1177/0961203312468963</article-id>
<article-id pub-id-type="publisher-id">10.1177_0961203312468963</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Papers</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Site differences in mild cognitive dysfunction (MCD) among patients with systemic lupus erythematosus (SLE)</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" corresp="yes">
<name><surname>Kozora</surname><given-names>E</given-names></name>
<xref ref-type="aff" rid="aff1-0961203312468963">1</xref>
<xref ref-type="aff" rid="aff5-0961203312468963">5</xref>
<xref ref-type="corresp" rid="corresp1-0961203312468963"/>
</contrib>
<contrib contrib-type="author">
<name><surname>Erkan</surname><given-names>D</given-names></name>
<xref ref-type="aff" rid="aff4-0961203312468963">4</xref>
<xref ref-type="aff" rid="aff5-0961203312468963">5</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>West</surname><given-names>SG</given-names></name>
<xref ref-type="aff" rid="aff6-0961203312468963">6</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Filley</surname><given-names>CM</given-names></name>
<xref ref-type="aff" rid="aff2-0961203312468963">2</xref>
<xref ref-type="aff" rid="aff3-0961203312468963">3</xref>
<xref ref-type="aff" rid="aff7-0961203312468963">7</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Zhang</surname><given-names>L</given-names></name>
<xref ref-type="aff" rid="aff8-0961203312468963">8</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Ramon</surname><given-names>G</given-names></name>
<xref ref-type="aff" rid="aff5-0961203312468963">5</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Duggan</surname><given-names>E</given-names></name>
<xref ref-type="aff" rid="aff1-0961203312468963">1</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Lockshin</surname><given-names>MD</given-names></name>
<xref ref-type="aff" rid="aff4-0961203312468963">4</xref>
<xref ref-type="aff" rid="aff5-0961203312468963">5</xref>
</contrib>
</contrib-group>
<aff id="aff1-0961203312468963"><label>1</label>Department of Medicine, National Jewish Health, USA</aff>
<aff id="aff2-0961203312468963"><label>2</label>Department of Neurology, University of Colorado School of Medicine, USA</aff>
<aff id="aff3-0961203312468963"><label>3</label>Department of Psychiatry, University of Colorado School of Medicine, USA</aff>
<aff id="aff4-0961203312468963"><label>4</label>Weill Medical College of Cornell University, USA</aff>
<aff id="aff5-0961203312468963"><label>5</label>Hospital for Special Surgery, USA</aff>
<aff id="aff6-0961203312468963"><label>6</label>Division of Rheumatology, University of Colorado School of Medicine, USA</aff>
<aff id="aff7-0961203312468963"><label>7</label>Denver Veterans Affairs Medical Center, USA</aff>
<aff id="aff8-0961203312468963"><label>8</label>Division of Bioinformatics and Biostatistics, National Jewish Health, USA</aff>
<author-notes>
<corresp id="corresp1-0961203312468963">Correspondence to: Elizabeth Kozora, National Jewish Health, 1400 Jackson St., Denver, CO 80206, USA. Email: <email>Kozorae@njhealth.org</email></corresp>
</author-notes>
<pub-date pub-type="epub-ppub">
<month>1</month>
<year>2013</year>
</pub-date>
<volume>22</volume>
<issue>1</issue>
<fpage>73</fpage>
<lpage>80</lpage>
<history>
<date date-type="received"><day>2</day><month>4</month><year>2012</year></date>
<date date-type="accepted"><day>24</day><month>10</month><year>2012</year></date>
</history>
<permissions>
<copyright-statement>© The Author(s), 2012. Reprints and permissions: http://www.sagepub.co.uk/journalsPermissions.nav</copyright-statement>
<copyright-year>2012</copyright-year>
<copyright-holder content-type="sage">SAGE Publications</copyright-holder>
</permissions>
<abstract>
<sec id="sec01-0961203312468963"><title>Background</title>
<p>Mild cognitive dysfunction (MCD) is common in patients with systemic lupus erythematosus (MCD-SLE) but few studies have investigated potential site differences.</p>
</sec>
<sec id="sec02-0961203312468963" sec-type="methods"><title>Methods</title>
<p>SLE patients from Denver, CO, and New York, NY, were enrolled in two different cognition studies employing similar screening methods. Using the resulting neuropsychological scores, cognitive impairment was calculated using a cognitive impairment index (CII).</p>
</sec>
<sec id="sec03-0961203312468963" sec-type="results"><title>Results</title>
<p>The rate of MCD-SLE was 24% at the Denver, CO, site and 60% at the New York, NY, site. The mean CII was 2.6 ± 2.3 versus 4.4 ± 2.7, respectively (<italic>p</italic> = 0.005). The NY participants had a significantly longer disease duration (<italic>p</italic> = 0.13) and higher American College of Rheumatology SLE criteria scores (<italic>p</italic> &gt; 0.001). NY participants had a higher frequency of impairment in semantic verbal fluency (<italic>p</italic> = 0.005), visuomotor speed (<italic>p</italic> = 0.013), and motor sequencing (<italic>p</italic> = 0.001). A correlation was found between cognitive impairment and SLE disease duration (<italic>p = </italic>0.03).</p>
</sec>
<sec id="sec04-0961203312468963" sec-type="conclusions"><title>Conclusions</title>
<p>The rate of MCD-SLE was greater in SLE patients from New York, NY, compared to patients in the Denver, CO, area. The greater duration of disease and higher prevalence of medical complications in the NY group might contribute to this difference. Findings suggest that MCD-SLE may differ by site, but future studies that better evaluate site or selection bias are recommended.</p>
</sec>
</abstract>
<kwd-group>
<kwd>SLE</kwd>
<kwd>neuropsychology</kwd>
<kwd>disease characteristics</kwd>
<kwd>site differences</kwd>
</kwd-group>
</article-meta>
</front>
<body>
<sec id="sec1-0961203312468963"><title>Background</title>
<p>Neuropsychiatric (NP) symptoms are common in patients with systemic lupus erythematosus (SLE), and up to 50% of patients with SLE demonstrate major psychiatric and neurologic disorders, indicating central nervous system (CNS) involvement.<sup><xref ref-type="bibr" rid="bibr1-0961203312468963">1</xref>,<xref ref-type="bibr" rid="bibr2-0961203312468963">2</xref></sup> In addition to overt disorders such as stroke and seizure disorder, more subtle changes including depression, anxiety, and cognitive dysfunction are included in the American College of Rheumatology (ACR) nomenclature for NP-SLE.<sup><xref ref-type="bibr" rid="bibr3-0961203312468963">3</xref></sup> Based on this nomenclature, cognitive dysfunction is one of 19 neuropsychiatric symptoms, defined as “significant deficits in any or all of the following cognitive functions: complex attention, executive skills (i.e. planning, organizing, sequencing), memory (i.e. learning, recall), visual-spatial processing, language (i.e. verbal fluency) and psychomotor speed.”<sup><xref ref-type="bibr" rid="bibr3-0961203312468963">3</xref></sup></p>
<p>Studies using standard neuropsychological tests have reported cognitive impairment in 14–75% of SLE patients, and a comprehensive review of this literature has been published.<sup><xref ref-type="bibr" rid="bibr4-0961203312468963">4</xref></sup> Inconsistencies across studies are largely methodological, including differences in the characteristics of the sample and the selection of tests used to classify impairment. Deficits in attention, verbal and nonverbal learning and recall, verbal and nonverbal fluency, complex psychomotor functions, visuospatial skills, and motor dexterity are identified when SLE patients are compared to healthy control subjects. SLE disease duration and activity, use of prednisone, and coexistence of depression have not been consistent mediators of cognitive dysfunction in SLE. Deficits in attention, learning and recall for verbal and nonverbal material, verbal fluency, complex psychomotor functions, visuospatial skills, and motor dexterity have been consistent across all SLE patients.</p>
<p>In SLE patients with overt NP syndromes such as stroke and seizure disorder, cognitive impairment has been documented in more than 50% of cases. Even without overt NP symptoms, cognitive dysfunction has been reported in approximately 25–50% of SLE patients.<sup><xref ref-type="bibr" rid="bibr4-0961203312468963">4</xref></sup> SLE patients who have demonstrated cognitive dysfunction without overt NP activity are commonly identified as mild cognitive dysfunction-SLE (MCD-SLE).<sup><xref ref-type="bibr" rid="bibr5-0961203312468963">5</xref></sup></p>
<p>The primary objective of this study was to compare the prevalence of MCD-SLE at two geographically different sites within the United States (US). We also compared demographic, behavioral, and health characteristics across the two sites.</p>
</sec>
<sec id="sec2-0961203312468963" sec-type="methods"><title>Methods</title>
<sec id="sec3-0961203312468963" sec-type="subjects"><title>Subjects</title>
<p>In this cross-sectional two-site study, SLE patients without overt NP disorders were enrolled for comprehensive assessments of cognitive functioning for two independent investigations: one conducted at National Jewish Health (NJH) in Denver, CO, and another at the Hospital for Special Surgery (HSS) in New York, NY. The studies were approved by the Institutional Review Boards (IRB) of both institutions: the Colorado Multiple Institutional Review Board at the University of Colorado (serving NJH) and the HSS IRB. The basic screening and inclusion/exclusion criteria across the two sites were similar (see details of research administration training and subject enrollment below). All patients had a diagnosis of SLE based on the ACR classification criteria.<sup><xref ref-type="bibr" rid="bibr6-0961203312468963">6</xref></sup> SLE subjects with any of the following were excluded: past or recent history of stroke; transient ischemic attack or vascular dementia; history or presence of other neurological disorder such as epilepsy, multiple sclerosis, prior traumatic brain injury, or CNS infection or tumor; past or current history of major psychiatric disorders (depression, schizophrenia, bipolar disorder); history of learning disability or substance abuse as defined by the Diagnostic and Statistical Manual of Mental Disorders, 4th edition (DSM-IV) standards<sup><xref ref-type="bibr" rid="bibr7-0961203312468963">7</xref></sup> and/or via diagnosis by a health professional; neuropsychological testing within the past year; other preexisting medical conditions potentially associated with cognitive dysfunction such as diabetes, hepatitis C, or human immunodeficiency infection; and current uncontrolled hypertension or cardiovascular compromise. At the New York site only, all subjects were female, and SLE subjects with a history of rheumatoid arthritis (RA), Sjögren's syndrome and/or antiphospholipid syndrome (APS) were specifically excluded (using negative lupus anti-coagulant test, anticardiolipin antibody (aCL) IgG/M/A, and anti-β2-glycoprotein-I antibody (aβ2GPI) IgG/M/A within six months of the study entry).</p>
</sec>
<sec id="sec4-0961203312468963"><title>Study procedures and measures</title>
<p>Eighty-four SLE patients were enrolled between August 2004 and April 2009 at NJH as part of a larger cognition and imaging study. The SLE subjects were recruited from the University of Colorado Hospital (UCH), NJH, and local rheumatology clinics, and eligibility was determined using a neuromedical phone screen and confirmation of SLE diagnosis and completion of disease activity indices as described previously.<sup><xref ref-type="bibr" rid="bibr8-0961203312468963">8</xref></sup> In New York, SLE patients were recruited from the HSS rheumatology clinic and private practices between October 2008 and June 2010. All eligible SLE patients had a 30-minute prescreening visit with their HSS study physician for a consent process, brief physical examination, the confirmation of SLE diagnosis, and the completion of disease activity indices.</p>
<p>After screening and eligibility determination was completed, the subjects were scheduled for neuropsychological testing at each site. At the testing appointment, a brief interview regarding subject demographics and additional neuromedical information was obtained using our previously utilized interview.<sup><xref ref-type="bibr" rid="bibr9-0961203312468963">9</xref></sup> Next, the extended ACR neuropsychological battery was administered.</p>
<p>The SLE research interview and screening procedures were originally developed at the Denver site. Rigorous training and standardization of these interview and screening procedures, along with test administration/scoring techniques, were consistently implemented over time to ensure the use of similar (or exactly the same) procedures between sites.<sup><xref ref-type="bibr" rid="bibr8-0961203312468963">8</xref>–<xref ref-type="bibr" rid="bibr10-0961203312468963">10</xref></sup> Individuals at the New York site were trained by the neuropsychologist and neuropsychology technicians from the Denver site who have more than 15 years of experience enrolling and testing SLE subjects. Training occurred during a two-day training seminar conducted at NJH in the fall of 2008 and included a review of interviewing procedures, standardized training in test administration and scoring, and a formal check-out procedure. Standardization of the interview and neuropsychological test administration and scoring has already been previously established.<sup><xref ref-type="bibr" rid="bibr11-0961203312468963">11</xref></sup> Throughout the study enrollment and testing of patients at the New York site, all test protocols were sent to the Denver site, where all records and scoring were double-checked by NJH laboratory technicians trained in multisite standardization procedures. All corrections were returned to the New York site prior to database entry.</p>
</sec>
<sec id="sec5-0961203312468963"><title>Neuropsychological tests</title>
<p>The SLE test battery recommended by the ACR<sup>3</sup> was administered, for which reliability and validity have been established.<sup><xref ref-type="bibr" rid="bibr12-0961203312468963">12</xref></sup> The Wechsler Test of Adult Reading<sup><xref ref-type="bibr" rid="bibr13-0961203312468963">13</xref></sup> — a vocabulary-based method for estimating pre-morbid intellectual level — was administered to ensure no difference in overall intelligence quotient (IQ) between groups.</p>
<p>The following tests and test scores used in this battery included: <italic>WAIS-III Digit Symbol Subtest-total score</italic> (Dig Sym),<sup><xref ref-type="bibr" rid="bibr14-0961203312468963">14</xref></sup> which requires psychomotor speed, concentration and graphomotor abilities; <italic>Trail Making Test-Part B-total time</italic> (Trails B),<sup><xref ref-type="bibr" rid="bibr15-0961203312468963">15</xref></sup> which measures psychomotor speed, attention and cognitive sequencing; <italic>Stroop Color and Word Test-Color-Word total score</italic> (Stroop),<sup><xref ref-type="bibr" rid="bibr16-0961203312468963">16</xref></sup> which measures complex attention and “shifting” of sets by naming color print for words written in different colors. The learning trials (summation of trials 1–5) and long delay free recall measures from the <italic>California Verbal Learning Test-Form II</italic> (CVLT-II)<sup><xref ref-type="bibr" rid="bibr17-0961203312468963">17</xref>,<xref ref-type="bibr" rid="bibr18-0961203312468963">18</xref></sup> were selected to measure learning and recall of verbal material. The immediate and 30-minute delayed recall of the <italic>Rey-Osterrieth Complex Figure Test</italic> (Rey-O Immediate, Rey-O Recall)<sup><xref ref-type="bibr" rid="bibr19-0961203312468963">19</xref>,<xref ref-type="bibr" rid="bibr20-0961203312468963">20</xref></sup> was selected to assess visual learning and memory. <italic>WAIS-III Letter Number Sequencing-total score</italic> (LNST)<sup><xref ref-type="bibr" rid="bibr14-0961203312468963">14</xref></sup> was selected as a measure of auditory working memory<italic>. Controlled Oral Word Association Test-total score</italic> (FAS) <italic>and Animal Naming Test-total score</italic> (Animals)<sup><xref ref-type="bibr" rid="bibr21-0961203312468963">21</xref></sup> were selected as measures of letter and category verbal fluency. <italic>Finger Tapping Test-Dominant</italic> (Tapping Dom) <italic>and Non-dominant hands</italic> (Tapping NDom)<sup><xref ref-type="bibr" rid="bibr15-0961203312468963">15</xref></sup> was used as a test of simple fine motor speed bilaterally. Additionally, four tests were identified as sensitive to SLE patients in our prior study<sup><xref ref-type="bibr" rid="bibr12-0961203312468963">12</xref></sup> and were included for analysis. <italic>WAIS-III Block Design-total score</italic> (Blocks)<sup><xref ref-type="bibr" rid="bibr22-0961203312468963">22</xref></sup> was obtained as a measure of visuoconstruction. <italic>Paced Auditory Serial Addition Test-total score</italic> (PASAT)<sup><xref ref-type="bibr" rid="bibr23-0961203312468963">23</xref></sup> was obtained as a measure of rapid auditory information processing; <italic>Digit Vigilance Test-total time</italic> (Dig Vig)<sup><xref ref-type="bibr" rid="bibr24-0961203312468963">24</xref></sup> was used to measure sustained visual attention; and the <italic>Category Test-total score</italic> (Category)<sup><xref ref-type="bibr" rid="bibr15-0961203312468963">15</xref></sup> was used as a measure of general abstracting ability and analytic skills.</p>
<p>A cognitive impairment index (CII) was calculated using 12 selected test scores from the ACR-SLE battery identified above.<sup><xref ref-type="bibr" rid="bibr12-0961203312468963">12</xref></sup> Each score was converted to T-scores using demographically corrected normative data.<sup><xref ref-type="bibr" rid="bibr18-0961203312468963">18</xref>,<xref ref-type="bibr" rid="bibr25-0961203312468963">25</xref>,<xref ref-type="bibr" rid="bibr26-0961203312468963">26</xref></sup> T-scores below 40 were considered impaired. The CII has a range of 0 to 12, with a higher number representing greater cognitive impairment.</p>
</sec>
<sec id="sec6-0961203312468963"><title>Disease and behavioral measures</title>
<p>Additional SLE descriptors included duration of disease (from time of clinical diagnosis), ACR diagnostic criteria (NP-SLE checklist), and recent SLE disease activity quantified using the Systemic Lupus Disease Activity Index (SLEDAI).<sup><xref ref-type="bibr" rid="bibr27-0961203312468963">27</xref></sup> The Beck Depression Inventory-Second Edition (BDI-II)<sup><xref ref-type="bibr" rid="bibr28-0961203312468963">28</xref></sup> was administered as a self-report measure of depressive symptoms in the two weeks prior to study completion.</p>
</sec>
<sec id="sec7-0961203312468963"><title>Data analysis</title>
<p>All statistical analyses were conducted with the SAS statistical analysis package (version 9.2; SAS Institute Inc., Cary, NC, USA). We first compared the two groups in terms of demographics (age, education, gender, and ethnicity) and health characteristics (duration of disease, disease activity/severity, and medication use). All continuous variables were compared using a non-parametric Wilcoxon rank sum test. All categorical variables were compared using a Fisher’s exact test. Next, the 12 neuropsychological measures (as T-scores) indicated in the cognitive functioning section were compared across groups using the Wilcoxon rank sum test. Finally, correlations were conducted between clinical measures and cognitive scores using Spearman correlation coefficients. For all analyses, two-tailed tests were used. <italic>p</italic> values less than 0.05 were designated statistically significant.</p>
</sec>
</sec>
<sec id="sec8-0961203312468963" sec-type="results"><title>Results</title>
<sec id="sec9-0961203312468963"><title>Demographic and health characteristics in Denver and New York SLE patients</title>
<p>As indicated in <xref ref-type="table" rid="table1-0961203312468963">Table 1</xref>, no significant differences between groups were found on demographics including age, education level, sex distribution, or race/ethnicity. In addition, estimated Full Scale IQ was calculated and did not differ across the groups. Health descriptors for the SLE patients, including length of diagnosis, SLEDAI total and percentage of subjects on prednisone, can be found in <xref ref-type="table" rid="table1-0961203312468963">Table 1</xref>. As indicated, the New York SLE subjects had a greater duration of disease and a higher score on the number of positive ACR criteria, although New York subjects showed lower current SLE disease activity (SLEDAI). As shown in <xref ref-type="fig" rid="fig1-0961203312468963">Figure 1</xref>, Denver SLE participants had a history or presence of the following ACR criteria/symptoms: malar rash (37.3%), discoid rash (13.3%), photosensitivity (54.2%), oral ulcers (32.5%), renal disorder (19.3%), hematologic disorder (41%), nonerosive arthritis (83.1%), positive antinuclear antibody (96.4%), immunologic disorder (68.7%) and pleuritis or pericarditis (22.9%). The New York SLE patients had a history or presence of the following ACR criteria/symptoms: malar rash (80%), discoid rash (5%), photosensitivity (65%), oral ulcers (30), renal disorder (50%), hematologic disorder (13/20%), nonerosive arthritis (90%), positive antinuclear antibody (100%), and immunologic disorder (90%). Statistically, the New York SLE patients had higher rates of malar rash (<italic>p</italic> = 0.001), renal involvement (<italic>p</italic> = 0.006) and serositis (<italic>p</italic> &lt; 0.001).
<fig id="fig1-0961203312468963" position="float"><label>Figure 1</label><caption><p>Percentage of subjects with specific ACR criteria across groups.</p>
<p>ACR criteria: revised American College of Rheumatology systemic lupus erythematosus classification criteria; ANA: antinuclear antibody.</p></caption><graphic xlink:href="10.1177_0961203312468963-fig1.tif"/>
</fig>
<table-wrap id="table1-0961203312468963" position="float"><label>Table 1</label><caption><p>Comparison of demographic and health characteristics of SLE subjects</p></caption>
<graphic alternate-form-of="table1-0961203312468963" xlink:href="10.1177_0961203312468963-table1.tif"/>
<table frame="hsides"><thead align="left">
<tr><th/>
<th>New York (<italic>n</italic>: 20)</th>
<th>Denver (<italic>n</italic>: 84)</th>
<th><italic>p</italic> value</th>
</tr></thead>
<tbody align="left">
<tr>
<td>Female (%)</td>
<td>100</td>
<td>94</td>
<td>1.000</td>
</tr>
<tr>
<td>Caucasian (%)</td>
<td>40</td>
<td>63</td>
<td>0.114</td>
</tr>
<tr>
<td>Mean age (years) and SD</td>
<td>36.5 ± 11.7</td>
<td>36.7 ± 8.7</td>
<td>0.642</td>
</tr>
<tr>
<td>Mean education (years) and SD</td>
<td>15.6<italic> ± </italic>2.4</td>
<td>14.6 ± 2.5</td>
<td>0.093</td>
</tr>
<tr>
<td>Mean ACR SLE criteria and SD</td>
<td>6.2 ± 1.47</td>
<td>4.7 ± 0.97</td>
<td><italic>&lt;0.001</italic></td>
</tr>
<tr>
<td>Mean diagnosis duration (months) and SD</td>
<td>154.8<italic> ± </italic>121.9</td>
<td>90.2 ± 78.7</td>
<td><italic>0.013</italic></td>
</tr>
<tr>
<td>Mean SLEDAI score and SD</td>
<td>2.2<italic> ± </italic>2.1</td>
<td>5.2<italic> ± </italic>5.4</td>
<td><italic>0.014</italic></td>
</tr>
<tr>
<td>Mean steroid dose and SD</td>
<td>3.7 ± 1.4</td>
<td>4.2 ± 0.67</td>
<td>0.932</td>
</tr>
<tr>
<td>% on prednisone</td>
<td>50.0</td>
<td>47.4</td>
<td>1.000</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn1-0961203312468963"><p>SLE: systemic lupus erythematosus; ACR: American College of Rheumatology; SLEDAI: Systemic Lupus Disease Activity Index.</p></fn></table-wrap-foot>
</table-wrap></p>
<p>As noted in <xref ref-type="table" rid="table1-0961203312468963">Table 1</xref>, there was no significant difference across the groups in terms of the percentage of patients on prednisone (New York = 47.4%, Denver = 50%). At the time of enrollment, medications for Denver SLE patients included: hydroxychloroquine (36%), other immunosuppressants (80%), antidepressants (23%), antihypertensives (31%), drugs to modify anxiety and depression (30%), thyroid medications (20%), and opioid analgesics (6%). For the New York SLE patients, medications at time of enrollment included: hydroxychloroquine (75%), other immunosuppressants (40%), antihypertensives (40%), and thyroid medications (5%).</p>
</sec>
<sec id="sec10-0961203312468963"><title>Neuropsychological test results in New York and Denver SLE patients</title>
<p>A comparison of the mean T-scores on individual tests can be found in <xref ref-type="table" rid="table2-0961203312468963">Table 2</xref>. The Denver SLE patients were significantly more impaired on measures of visuomotor speed (Dig Sym), motor sequencing (speed and cognitive flexibility) (Trails B), and visual attention (Dig Vig). In terms of a global index, the New York SLE subjects had a greater number of impaired tests from the CII compared to Denver SLE subjects (range 0–12).
<table-wrap id="table2-0961203312468963" position="float"><label>Table 2</label><caption><p>Composite scores and individual test T-scores on neuropsychological measures by group</p></caption>
<graphic alternate-form-of="table2-0961203312468963" xlink:href="10.1177_0961203312468963-table2.tif"/>
<table frame="hsides"><thead align="left">
<tr><th rowspan="2">Variable</th>
<th colspan="2">New York (<italic>n</italic>: 84)<hr/></th>
<th colspan="2">Denver (<italic>n</italic>: 20)<hr/></th>
<th/>
</tr>
<tr><th>Mean</th>
<th>SD</th>
<th>Mean</th>
<th>SD</th>
<th><italic>p</italic> value</th>
</tr></thead>
<tbody align="left">
<tr>
<td>COGNITIVE IMPAIRMENT INDEX</td>
<td/>
<td/>
<td/>
<td/>
<td/>
</tr>
<tr>
<td>No. of ACR impaired cognitive test scores (range 0–12)</td>
<td>4.4</td>
<td>2.7</td>
<td>2.6</td>
<td>2.3</td>
<td><italic>0.005</italic></td>
</tr>
<tr>
<td>INDIVIDUAL COGNITIVE TEST T-SCORES</td>
<td/>
<td/>
<td/>
<td/>
<td/>
</tr>
<tr>
<td>*WAIS-III Digit Symbol</td>
<td>40.1</td>
<td>12.3</td>
<td>48.1</td>
<td>9.9</td>
<td><italic>0.012</italic></td>
</tr>
<tr>
<td>*WAIS-III Letter-Number Sequencing Test</td>
<td>48.6</td>
<td>10.4</td>
<td>50.7</td>
<td>9.8</td>
<td>0.245</td>
</tr>
<tr>
<td>*Stroop Color-Word Test</td>
<td>48.9</td>
<td>10.9</td>
<td>50.8</td>
<td>8.5</td>
<td>0.318</td>
</tr>
<tr>
<td>*Trail Making B</td>
<td>41.0</td>
<td>11.2</td>
<td>50.2</td>
<td>10.8</td>
<td><italic>0.002</italic></td>
</tr>
<tr>
<td>*FAS (Letter Fluency)</td>
<td>44.0</td>
<td>10.6</td>
<td>45.6</td>
<td>10.0</td>
<td>0.627</td>
</tr>
<tr>
<td>*Animals (Semantic Fluency)</td>
<td>44.2</td>
<td>13.6</td>
<td>49.2</td>
<td>8.9</td>
<td>0.132</td>
</tr>
<tr>
<td>*CVLT-II Immediate (Learning)</td>
<td>50.5</td>
<td>14.2</td>
<td>48.9</td>
<td>11.9</td>
<td>0.863</td>
</tr>
<tr>
<td>*CVLT-II Recall</td>
<td>46.0</td>
<td>16.3</td>
<td>47.4</td>
<td>13.0</td>
<td>0.898</td>
</tr>
<tr>
<td>*Rey-O Immediate Recall</td>
<td>37.9</td>
<td>16.5</td>
<td>40.1</td>
<td>12.4</td>
<td>0.394</td>
</tr>
<tr>
<td>*Rey-O Delayed Recall</td>
<td>36.9</td>
<td>16.1</td>
<td>38.3</td>
<td>12.7</td>
<td>0.626</td>
</tr>
<tr>
<td>*Tapping: Dominant hand</td>
<td>51.2</td>
<td>12.2</td>
<td>50.7</td>
<td>10.7</td>
<td>0.763</td>
</tr>
<tr>
<td>*Tapping: Non-dominant hand</td>
<td>49.5</td>
<td>10.8</td>
<td>49.5</td>
<td>9.5</td>
<td>0.756</td>
</tr>
<tr>
<td>WAIS-III Block Design</td>
<td>48.7</td>
<td>12.3</td>
<td>51.1</td>
<td>11.6</td>
<td>0.305</td>
</tr>
<tr>
<td>PASAT</td>
<td>43.2</td>
<td>12.3</td>
<td>46.0</td>
<td>10.1</td>
<td>0.376</td>
</tr>
<tr>
<td>Digit Vigilance Test</td>
<td>42.3</td>
<td>10.1</td>
<td>49.3</td>
<td>9.9</td>
<td><italic>0.007</italic></td>
</tr>
<tr>
<td>Category Test</td>
<td>48.2</td>
<td>9.4</td>
<td>46.0</td>
<td>12.0</td>
<td>0.355</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn2-0961203312468963"><p>ACR: American College of Rheumatology; WAIS: Wechsler Adult Intelligence Scale; FAS: Controlled Oral Word Association Test; Animals: Animal Naming Test; CVLT-II: California Verbal Learning Test-Form II; REY-O: Rey-Osterrieth Complex Figure Test; Tapping: Finger Tapping Test; PASAT: Paced Auditory Serial Addition Test. *Indicates the twelve test scores used to calculate the cognitive impairment index (CII).</p></fn></table-wrap-foot>
</table-wrap></p>
<p><xref ref-type="fig" rid="fig2-0961203312468963">Figure 2</xref> demonstrates the percentage of impairment across the individual tests as well as percentage of patients with four or more of the 12 tests from the CII (12). Using the CII impairment level, 60% (12/20) of the New York SLE patients and 23.8% (20/84) of the Denver SLE patients were cognitively impaired. New York participants had a higher frequency of impairment in semantic verbal fluency (<italic>p</italic> = 0.005), visuomotor speed (<italic>p</italic> = 0.013), and motor sequencing (<italic>p</italic> = 0.001). For the entire SLE group, there was a correlation between cognitive impairment and SLE disease duration (<italic>p = </italic>0.04) but not with total ACR SLE criteria score (<italic>p</italic> = 0.33).
<fig id="fig2-0961203312468963" position="float"><label>Figure 2</label><caption><p>Percentage of impairment on neuropsychological measures.</p>
<p>CVLT: California Verbal Learning Test-II; Rey-O: Rey-Osterrieth Complex Figure Test; Dig Sym: WAIS-III Digit Symbol Test; LNST: WAIS-III Letter-Number Sequencing Test; Stroop: Stroop Color and Word Test; PASAT: Paced Auditory Serial Addition Test; Dig Vig: Digit Vigilance Test; Trails B: Trail Making Test Part B; FAS: Verbal Fluency; Animals: Category Fluency; Category: Category Test; Blocks: WAIS-III Block Design Test; Tapping: Finger Tapping Test (dominant hand and non-dominant hand); CII: Cognitive Impairment Index.</p></caption><graphic xlink:href="10.1177_0961203312468963-fig2.tif"/>
</fig></p>
</sec>
<sec id="sec11-0961203312468963"><title>Subanalysis of demographics, health characteristics and cognitive functions in matched SLE patients across sites</title>
<p>In order to limit bias introduced by a larger sample size (<italic>n</italic> = 84) in Denver compared to the sample size in New York (<italic>n</italic> = 20), 20 SLE patients from the Denver site were matched to the 20 New York subjects by age (within four years), education (within two years), gender (all female), and ethnicity (identical). Using these criteria, there were no differences in demographics between the two groups, but in terms of health characteristics, SLE patients in New York had a significantly greater length of diagnosis (154.8 months, SD = 121.9) compared to the Denver SLE patients (78.6, SD = 78.7 (<italic>p</italic> = 0.1016)). New York patients also had a higher ACR criteria level (<italic>p</italic> = 0.001) with significantly higher levels of malar rash (<italic>p</italic> = 0.006), photosensitivity (<italic>p</italic> = 0.034), and serositis (<italic>p</italic> = 0.002). Using the CII, 25% of the Denver SLE patients were cognitively impaired compared to 60% in New York. There was a trend difference for greater number of impaired cognitive tests (range 0–12) (New York = 4.6 ± 2.9 compared to Denver 2.9 ± 2.6; <italic>p</italic> = 0.07), and the New York site had a significantly greater frequency of impairment on semantic fluency (<italic>p</italic> = 0.04) and visuomotor speed (<italic>p</italic> = 0.019).</p>
</sec>
</sec>
<sec id="sec12-0961203312468963" sec-type="discussion"><title>Discussion</title>
<p>This study found that 60% of SLE subjects from the New York, NY, site had MCD-SLE compared to 23% of the SLE subjects from the Denver, CO, site. Specifically, the New York SLE patients had greater deficits in areas of verbal fluency, visuomotor speed and sequencing skills. To adjust for differences in sample size, we selected 20 SLE patients from the Denver group to match to the New York group. Re-analysis continued to disclose large differences in the frequency of MCD-SLE (60% in New York compared to 25% in Denver) although the number of impaired scores was slightly reduced with the matched group.</p>
<p>Our prior studies in the Denver area have demonstrated MCD-SLE in 23% to 31% of our SLE samples. In other studies of MCD-SLE, numbers have ranged from 14% to 54%, with estimates at or lower than 20% in some studies<sup><xref ref-type="bibr" rid="bibr29-0961203312468963">29</xref>–<xref ref-type="bibr" rid="bibr32-0961203312468963">32</xref></sup> and at or above 40% in other studies.<sup><xref ref-type="bibr" rid="bibr33-0961203312468963">33</xref>–<xref ref-type="bibr" rid="bibr35-0961203312468963">35</xref></sup> Many of these studies were difficult to compare to the Denver studies because of differences in subject selection, test selection, and definition of cognitive impairment. In this particular study, the subject selection, interviewing process, tests administered, and scoring were identical; therefore, this is the first study to demonstrate such a significant difference in MCD-SLE based on site and possibly geographic parameters.</p>
<p>In order to understand the etiological factors related to the higher rate of MCD-SLE in the New York compared to Denver sites, we compared demographic, behavioral, and health characteristics across the two sites. We did not find differences in age, education, ethnicity, disease severity or depression between the groups. We did find greater duration of disease and a higher prevalence of medical complications (via the ACR criteria) in the New York SLE patients. There was a direct correlation between duration of disease and the global cognitive measure when combining our two SLE samples. Disease duration, disease severity, and prednisone dose have not been related to cognition in our prior studies of MCD-SLE in Denver;<sup><xref ref-type="bibr" rid="bibr8-0961203312468963">8</xref>–<xref ref-type="bibr" rid="bibr10-0961203312468963">10</xref></sup> however, in other studies using patients with more severe NP-SLE,<sup><xref ref-type="bibr" rid="bibr36-0961203312468963">36</xref>–<xref ref-type="bibr" rid="bibr42-0961203312468963">42</xref></sup> associations between SLE disease characteristics and cognitive functioning have been found.</p>
<p>Papero et al.<sup><xref ref-type="bibr" rid="bibr40-0961203312468963">40</xref></sup> reported that a longer duration of SLE was related to lower cognitive status in adolescents, a finding that could suggest early-onset SLE patients have a higher risk of CNS involvement; however, no other studies have replicated this finding regarding duration of disease and cognitive dysfunction in adults. Hanly et al.<sup><xref ref-type="bibr" rid="bibr38-0961203312468963">38</xref></sup> reported a trend (but not statistically significant) relationship between scores on a standardized measure of SLE disease activity and MCD-SLE. These investigators also reported that history of serositis was more common in cognitively impaired SLE patients. Using the same group of SLE patients, Fisk et al.<sup><xref ref-type="bibr" rid="bibr37-0961203312468963">37</xref></sup> reported that greater SLE disease activity was associated with impaired immediate memory and attention.</p>
<p>Neuroimaging was not analyzed in this study, but cognitive impairment in these SLE patients could be explained by at least two cerebral neuropathologic processes. First, microstructural white matter abnormalities in the frontal lobes have been correlated with deficits in processing speed, executive function, and attention in MCD-SLE<sup><xref ref-type="bibr" rid="bibr43-0961203312468963">43</xref>,<xref ref-type="bibr" rid="bibr44-0961203312468963">44</xref></sup> leading to the designation of MCD-SLE.<sup><xref ref-type="bibr" rid="bibr44-0961203312468963">44</xref></sup> Second, neurometabolic abnormalities in the hippocampus have also been associated with MCD-SLE.<sup><xref ref-type="bibr" rid="bibr45-0961203312468963">45</xref></sup> Future studies to assess the relative contributions of these, and possibly other, SLE brain lesions in the absence of NP syndromes will therefore be informative. Immune mechanisms also merit further study. Serum analysis of autoantibodies (i.e. antiphospholipid antibodies (aPL), anti-N-methyl D-aspartate (anti-NMDA)) and proinflammatory cytokines (interleukin (IL)-1, IL-6, interferon (INF)-alpha and gamma) showed no differences between SLE and controls in Denver.<sup><xref ref-type="bibr" rid="bibr5-0961203312468963">5</xref></sup> Immune studies were not available and/or performed in New York but might have revealed immune-mediated correlations with cognition.</p>
<p>In conclusion, although varying sample size and baseline characteristics limit our findings, our study suggests different rates of MCD-SLE in sites located in different parts of the country. The rate of MCD-SLE was greater in SLE patients from New York, NY, compared to patients in the Denver, CO, area. The greater duration of disease and higher prevalence of medical complications in the New York group might contribute to this difference. The New York and Denver studies were developed separately, with a much smaller sample size in New York; thus, future studies that match and increase the sample sizes are necessary to confirm and explore these differences. As many variables may influence cognitive outcome, attribution of causality on a single study is not possible. For example, a recent study by Katz et al. suggested that obesity and inactivity are associated with cognitive impairment in patients with SLE.<sup><xref ref-type="bibr" rid="bibr46-0961203312468963">46</xref></sup> Investigating additional environmental, health-related and socioeconomic factors across sites may be useful for improved understanding of site differences in cognition for SLE patients in future studies.</p>
</sec>
</body>
<back>
<ack>
<title>Acknowledgments</title>
<p>We would like to acknowledge members of the research team in Denver, CO: David Arciniegas, MD, Mark Brown, PhD, David Miller, PhD, and Jamie Pelzman, BA; and the research team at the Hospital for Special Surgery in New York, NY: Aziz Ulug, PhD, Robert Zimmerman, MD, An Vo, PhD, and Joann Vega, CCRC. We are grateful for their contributions and dedication to these research studies.</p></ack>
<sec id="sec17-0961203312468963"><title>Funding</title>
<p>The National Jewish Health study in Denver, CO, was supported by the US National Institutes of Health/National Institute of Musculoskeletal and Skin Diseases (grant R01 AR049152-02S1). The Hospital for Special Surgery study in New York, NY, was supported by the Mary Kirkland Foundation for Lupus Research (New York, NY, USA).</p>
</sec>
<sec id="sec18-0961203312468963"><title>Conflict of interest</title>
<p>None declared.</p>
</sec>
<ref-list>
<title>References</title>
<ref id="bibr1-0961203312468963"><label>1</label><citation citation-type="book"><person-group person-group-type="author"><name><surname>Bluestein</surname><given-names>HG</given-names></name></person-group>. In: <person-group person-group-type="editor"><name><surname>Lahita</surname><given-names>RG</given-names></name></person-group>. <article-title>The central nervous system in systemic lupus erythematosus</article-title>. <source>Systemic lupus erythematosus</source>, <edition>2nd ed</edition>. <publisher-loc>New York</publisher-loc>: <publisher-name>Churchill Livingstone Inc.</publisher-name>,  <year>1992</year>. p. <fpage>639</fpage>–<lpage>655</lpage>.</citation></ref>
<ref id="bibr2-0961203312468963"><label>2</label><citation citation-type="book"><person-group person-group-type="author"><name><surname>West</surname><given-names>SG</given-names></name></person-group>. In: <person-group person-group-type="editor"><name><surname>Wallace</surname><given-names>DJ</given-names></name><name><surname>Hahn</surname><given-names>BH</given-names></name></person-group>. <article-title>The nervous system</article-title>. <source>Dubois’ lupus erythematosus</source>, <edition>7th ed</edition>. <publisher-loc>Philadelphia</publisher-loc>: <publisher-name>Lippincott, Williams &amp; Wilkins</publisher-name>,  <year>2007</year>. p. <fpage>707</fpage>–<lpage>746</lpage>.</citation></ref>
<ref id="bibr3-0961203312468963"><label>3</label><citation citation-type="other"><comment>The American College of Rheumatology nomenclature and case definitions for neuropsychiatric lupus syndromes. <italic>Arthritis Rheum</italic> 1999; 42: 599–608. PMID: 10211873</comment>.</citation></ref>
<ref id="bibr4-0961203312468963"><label>4</label><citation citation-type="book"><person-group person-group-type="author"><name><surname>Kozora</surname><given-names>E</given-names></name></person-group>. In: <person-group person-group-type="editor"><name><surname>Morgan</surname><given-names>JE</given-names></name><name><surname>Ricker</surname><given-names>JH</given-names></name></person-group>. <article-title>Neuropsychological functioning in systemic lupus erythematosus</article-title>. <source>Textbook of clinical neuropsychology</source>, <publisher-loc>New York</publisher-loc>: <publisher-name>Taylor and Francis</publisher-name>, <year>2008</year>. p. <fpage>636</fpage>–<lpage>649</lpage>.</citation></ref>
<ref id="bibr5-0961203312468963"><label>5</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kozora</surname><given-names>E</given-names></name><name><surname>Filley</surname><given-names>CM</given-names></name><name><surname>Zhang</surname><given-names>L</given-names></name><etal/></person-group>. <article-title>Immune function and brain abnormalities in systemic lupus erythematosus patients without overt neuropsychiatric manifestations</article-title>. <source>Lupus</source> <year>2012</year>; <volume>21</volume>: <fpage>402</fpage>–<lpage>411</lpage>. <comment>Epub 14 Dec 2011)</comment>.</citation></ref>
<ref id="bibr6-0961203312468963"><label>6</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hochberg</surname><given-names>MC</given-names></name></person-group>. <article-title>Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus</article-title>. <source>Arthritis Rheum</source> <year>1997</year>; <volume>40</volume>: <fpage>1725</fpage>–<lpage>1725</lpage>. <comment>PMID: 9 324 032</comment>.</citation></ref>
<ref id="bibr7-0961203312468963"><label>7</label><citation citation-type="book"><person-group person-group-type="author"><name><surname>First</surname><given-names>MB</given-names></name><name><surname>Spitzer</surname><given-names>RL</given-names></name><name><surname>Gibbon</surname><given-names>M</given-names></name><name><surname>Williams</surname><given-names>JB</given-names></name></person-group> (eds), <source>Structured clinical interview for DSM-IV axis I disorders, clinician version (SCID-CV)</source>, <publisher-loc>Washington, DC</publisher-loc>: <publisher-name>American Psychiatric Press Inc</publisher-name>, <year>1996</year>.</citation></ref>
<ref id="bibr8-0961203312468963"><label>8</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kozora</surname><given-names>E</given-names></name><name><surname>Hanly</surname><given-names>JG</given-names></name><name><surname>Lapteva</surname><given-names>L</given-names></name><name><surname>Filley</surname><given-names>CM</given-names></name></person-group>. <article-title>Cognitive dysfunction in systemic lupus erythematosus: Past, present, and future</article-title>. <source>Arthritis Rheum</source> <year>2008</year>; <volume>58</volume>: <fpage>3286</fpage>–<lpage>3298</lpage>.</citation></ref>
<ref id="bibr9-0961203312468963"><label>9</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kozora</surname><given-names>E</given-names></name><name><surname>Thompson</surname><given-names>LL</given-names></name><name><surname>West</surname><given-names>SG</given-names></name><name><surname>Kotzin</surname><given-names>BL</given-names></name></person-group>. <article-title>Analysis of cognitive and psychological deficits in systemic lupus erythematosus patients without overt central nervous system disease</article-title>. <source>Arthritis Rheum</source> <year>1996</year>; <volume>39</volume>: <fpage>2035</fpage>–<lpage>2045</lpage>. <comment>. PMID: 8 961 909</comment>.</citation></ref>
<ref id="bibr10-0961203312468963"><label>10</label><citation citation-type="book"><person-group person-group-type="author"><name><surname>Kozora</surname><given-names>E</given-names></name><name><surname>Gerber</surname><given-names>D</given-names></name></person-group>. In: <person-group person-group-type="editor"><name><surname>Lowell</surname><given-names>M</given-names></name><name><surname>Enchemendia</surname><given-names>R</given-names></name><name><surname>Borth</surname><given-names>J</given-names></name><etal/></person-group>. <article-title>Special considerations: Implications of neuropsychological testing in professional athletes</article-title>. <source>Traumatic brain injury in sports: An international neuropsychological perspective</source>, <publisher-loc>Lisse, The Netherlands</publisher-loc>: <publisher-name>Swets &amp; Zeitlinger</publisher-name>, <year>2004</year>. p. <fpage>357</fpage>–<lpage>393</lpage>.</citation></ref>
<ref id="bibr11-0961203312468963"><label>11</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kozora</surname><given-names>E</given-names></name><name><surname>Kongs</surname><given-names>S</given-names></name><name><surname>Box</surname><given-names>T</given-names></name><etal/></person-group>. <article-title>Training and management of a multisite neuropsychological testing protocol for the Department of Veterans Affairs cooperative study evaluating on- and off-pump coronary artery bypass graft procedures</article-title>. <source>Clin Neuropsychol</source> <year>2007</year>; <volume>21</volume>: <fpage>653</fpage>–<lpage>662</lpage>.</citation></ref>
<ref id="bibr12-0961203312468963"><label>12</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kozora</surname><given-names>E</given-names></name><name><surname>Ellison</surname><given-names>MC</given-names></name><name><surname>West</surname><given-names>S</given-names></name></person-group>. <article-title>Reliability and validity of the proposed American College of Rheumatology neuropsychological battery for systemic lupus erythematosus</article-title>. <source>Arthritis Rheum</source> <year>2004</year>; <volume>51</volume>: <fpage>810</fpage>–<lpage>818</lpage>.</citation></ref>
<ref id="bibr13-0961203312468963"><label>13</label><citation citation-type="book"><person-group person-group-type="author"><name><surname>Wechsler</surname><given-names>D</given-names></name></person-group> (eds), <source>Weschler test of adult reading</source>, <publisher-loc>San Antonio, TX</publisher-loc>: <publisher-name>Psychological Corporation Inc</publisher-name>, <year>2001</year>.</citation></ref>
<ref id="bibr14-0961203312468963"><label>14</label><citation citation-type="book"><person-group person-group-type="author"><name><surname>Wechsler</surname><given-names>D</given-names></name></person-group> (eds), <source>Wechsler adult intelligence scale-third edition</source>, <publisher-loc>San Antonio, TX</publisher-loc>: <publisher-name>Psychological Corporation Inc</publisher-name>, <year>1997</year>.</citation></ref>
<ref id="bibr15-0961203312468963"><label>15</label><citation citation-type="book"><person-group person-group-type="author"><name><surname>Reitan</surname><given-names>RM</given-names></name><name><surname>Wolfson</surname><given-names>D</given-names></name></person-group> (eds), <source>The Halstead-Reitan neuropsychology test battery</source>, <publisher-loc>Tucson, AZ</publisher-loc>: <publisher-name>Neuropsychological Press</publisher-name>, <year>1988</year>.</citation></ref>
<ref id="bibr16-0961203312468963"><label>16</label><citation citation-type="book"><person-group person-group-type="author"><name><surname>Golden</surname><given-names>CJ</given-names></name></person-group> (eds), <source>Stroop color and word test</source>, <publisher-loc>Chicago, IL</publisher-loc>: <publisher-name>Stoelting</publisher-name>, <year>1978</year>.</citation></ref>
<ref id="bibr17-0961203312468963"><label>17</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Deweer</surname><given-names>B</given-names></name><name><surname>Lehéricy</surname><given-names>S</given-names></name><name><surname>Pillon</surname><given-names>B</given-names></name><etal/></person-group>. <article-title>Memory disorders in probable Alzheimer's disease: The role of hippocampal atrophy as shown with MRI</article-title>. <source>J Neurol Neurosurg Psychiatry</source> <year>1995</year>; <volume>58</volume>: <fpage>590</fpage>–<lpage>597</lpage>. <comment>. PMID: 7 745 409</comment>.</citation></ref>
<ref id="bibr18-0961203312468963"><label>18</label><citation citation-type="book"><person-group person-group-type="author"><name><surname>Delis</surname><given-names>D</given-names></name><name><surname>Kramer</surname><given-names>J</given-names></name><name><surname>Kaplan</surname><given-names>E</given-names></name><name><surname>Ober</surname><given-names>B</given-names></name></person-group> (eds), <source>California verbal learning test-second edition</source>, <publisher-loc>San Antonio, TX</publisher-loc>: <publisher-name>Psychological Corporation Inc</publisher-name>, <year>2000</year>.</citation></ref>
<ref id="bibr19-0961203312468963"><label>19</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Boone</surname><given-names>KB</given-names></name><name><surname>Lesser</surname><given-names>IM</given-names></name><name><surname>Hill-Gutierrez</surname><given-names>E</given-names></name><name><surname>Berman</surname><given-names>NG</given-names></name><name><surname>D'Elia</surname><given-names>LF</given-names></name></person-group>. <article-title>Rey-Osterrieth Complex figure performance in healthy older adults: Relationship to age, education, sex and IQ</article-title>. <source>Clin Neuropsychol</source> <year>1993</year>; <volume>7</volume>: <fpage>22</fpage>–<lpage>28</lpage>.</citation></ref>
<ref id="bibr20-0961203312468963"><label>20</label><citation citation-type="book"><person-group person-group-type="author"><name><surname>Meyers</surname><given-names>JE</given-names></name><name><surname>Meyers</surname><given-names>KR</given-names></name></person-group> (eds), <source>Rey Complex Figure Test and Recognition Trial: Professional manual</source>, <publisher-loc>Odessa, FL</publisher-loc>: <publisher-name>Psychological Assessment Resources Inc</publisher-name>, <year>1995</year>.</citation></ref>
<ref id="bibr21-0961203312468963"><label>21</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Borkowski</surname><given-names>JG</given-names></name><name><surname>Benton</surname><given-names>AL</given-names></name><name><surname>Spreen</surname><given-names>O</given-names></name></person-group>. <article-title>Word fluency and brain damage</article-title>. <source>Neuropsychologia</source> <year>1967</year>; <volume>5</volume>: <fpage>135</fpage>–<lpage>140</lpage>.</citation></ref>
<ref id="bibr22-0961203312468963"><label>22</label><citation citation-type="book"><person-group person-group-type="author"><name><surname>Wechsler</surname><given-names>D</given-names></name></person-group> (eds), <source>Wechsler adult intelligence scale – revised manual</source>, <publisher-loc>San Antonio, TX</publisher-loc>: <publisher-name>Psychological Corporation Inc.</publisher-name>, <year>1981</year>.</citation></ref>
<ref id="bibr23-0961203312468963"><label>23</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Gronwall</surname><given-names>DM</given-names></name></person-group>. <article-title>Paced auditory serial additional test: A measure of recovery from concussion</article-title>. <source>Percept Motor Skills</source> <year>1977</year>; <volume>44</volume>: <fpage>367</fpage>–<lpage>373</lpage>.</citation></ref>
<ref id="bibr24-0961203312468963"><label>24</label><citation citation-type="other"><comment>Lewis R and Kupke T (eds) The Lafayette Clinical Repeatable Neuropsychological Test Battery: Its development and research applications. Meeting of the Southeastern Psychological Association, Hollywood, FL, May 1977</comment>.</citation></ref>
<ref id="bibr25-0961203312468963"><label>25</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Gladsjo</surname><given-names>JA</given-names></name><name><surname>Schuman</surname><given-names>CC</given-names></name><name><surname>Evans</surname><given-names>JD</given-names></name><name><surname>Peavy</surname><given-names>GM</given-names></name><name><surname>Miller</surname><given-names>SW</given-names></name><name><surname>Heaton</surname><given-names>RK</given-names></name></person-group>. <article-title>Norms for letter and category fluency: Demographic corrections for age, education and ethnicity</article-title>. <source>Assessment</source> <year>1999</year>; <volume>6</volume>: <fpage>147</fpage>–<lpage>178</lpage>.</citation></ref>
<ref id="bibr26-0961203312468963"><label>26</label><citation citation-type="book"><person-group person-group-type="author"><name><surname>Heaton</surname><given-names>R</given-names></name><name><surname>Heaton</surname><given-names>S</given-names></name></person-group>. In: <person-group person-group-type="editor"><name><surname>Filskov</surname><given-names>SB</given-names></name><name><surname>Boll</surname><given-names>TJ</given-names></name></person-group>. <article-title>Testing the impaired patient</article-title>. <source>Handbook of clinical neuropsychology</source>, <publisher-loc>New York</publisher-loc>: <publisher-name>John Wiley &amp; Sons</publisher-name>, <year>1980</year>.</citation></ref>
<ref id="bibr27-0961203312468963"><label>27</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bombardier</surname><given-names>C</given-names></name><name><surname>Gladman</surname><given-names>DD</given-names></name><name><surname>Urowitz</surname><given-names>MB</given-names></name><name><surname>Caron</surname><given-names>D</given-names></name><name><surname>Chang</surname><given-names>CH</given-names></name></person-group>. <article-title>Derivation of the SLEDAI. A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE</article-title>. <source>Arthritis Rheum</source> <year>1992</year>; <volume>35</volume>: <fpage>630</fpage>–<lpage>640</lpage>. <comment>. PMID: 1 599 520</comment>.</citation></ref>
<ref id="bibr28-0961203312468963"><label>28</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Beck</surname><given-names>AT</given-names></name><name><surname>Steer</surname><given-names>RA</given-names></name><name><surname>Ball</surname><given-names>R</given-names></name><name><surname>Ranieri</surname><given-names>W</given-names></name></person-group>. <article-title>Comparison of Beck Depression Inventories -IA and -II in psychiatric outpatients</article-title>. <source>J Pers Assess</source> <year>1996</year>; <volume>67</volume>: <fpage>588</fpage>–<lpage>597</lpage>.</citation></ref>
<ref id="bibr29-0961203312468963"><label>29</label><citation citation-type="book"><person-group person-group-type="author"><name><surname>Koffler</surname><given-names>S</given-names></name></person-group>. In: <person-group person-group-type="editor"><name><surname>Lahita</surname><given-names>RG</given-names></name></person-group>. <article-title>The role of neuropsychological testing in systemic lupus erythematosus</article-title>. <source>Systemic lupus erythematosus</source>, <publisher-loc>New York</publisher-loc>: <publisher-name>John Wiley &amp; Sons</publisher-name>, <year>1987</year>. p. <fpage>847</fpage>–<lpage>853</lpage>.</citation></ref>
<ref id="bibr30-0961203312468963"><label>30</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hay</surname><given-names>EM</given-names></name><name><surname>Black</surname><given-names>D</given-names></name><name><surname>Huddy</surname><given-names>A</given-names></name><etal/></person-group>. <article-title>Psychiatric disorder and cognitive impairment in systemic lupus erythematosus</article-title>. <source>Arthritis Rheum</source> <year>1992</year>; <volume>35</volume>: <fpage>411</fpage>–<lpage>416</lpage>. <comment>. PMID: 1 567 490</comment>.</citation></ref>
<ref id="bibr31-0961203312468963"><label>31</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hanly</surname><given-names>JG</given-names></name><name><surname>Walsh</surname><given-names>NM</given-names></name><name><surname>Sangalang</surname><given-names>V</given-names></name></person-group>. <article-title>Brain pathology in systemic lupus erythematosus</article-title>. <source>J Rheumatol</source> <year>1992</year>; <volume>19</volume>: <fpage>732</fpage>–<lpage>741</lpage>.</citation></ref>
<ref id="bibr32-0961203312468963"><label>32</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Carlomagno</surname><given-names>S</given-names></name><name><surname>Migliaresi</surname><given-names>S</given-names></name><name><surname>Ambrosone</surname><given-names>L</given-names></name><name><surname>Sannino</surname><given-names>M</given-names></name><name><surname>Sanges</surname><given-names>G</given-names></name><name><surname>Di Iorio</surname><given-names>G</given-names></name></person-group>. <article-title>Cognitive impairment in systemic lupus erythematosus: A follow-up study</article-title>. <source>J Neurol</source> <year>2000</year>; <volume>247</volume>: <fpage>273</fpage>–<lpage>279</lpage>. <comment>. PMID: 10 836 619</comment>.</citation></ref>
<ref id="bibr33-0961203312468963"><label>33</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Carbotte</surname><given-names>RM</given-names></name><name><surname>Denburg</surname><given-names>SD</given-names></name><name><surname>Denburg</surname><given-names>JA</given-names></name></person-group>. <article-title>Prevalence of cognitive impairment in systemic lupus erythematosus</article-title>. <source>J Nerv Men Dis</source> <year>1986</year>; <volume>174</volume>: <fpage>357</fpage>–<lpage>364</lpage>. <comment>. PMID: 3 711 879</comment>.</citation></ref>
<ref id="bibr34-0961203312468963"><label>34</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Denburg</surname><given-names>JA</given-names></name><name><surname>Carbotte</surname><given-names>RM</given-names></name><name><surname>Denburg</surname><given-names>SD</given-names></name></person-group>. <article-title>Neuronal antibodies and cognitive function in systemic lupus erythematosus</article-title>. <source>Neurology</source> <year>1987</year>; <volume>37</volume>: <fpage>464</fpage>–<lpage>467</lpage>. <comment>. PMID: 3 822 139</comment>.</citation></ref>
<ref id="bibr35-0961203312468963"><label>35</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Wekking</surname><given-names>EM</given-names></name><name><surname>Nossent</surname><given-names>JC</given-names></name><name><surname>van Dam</surname><given-names>AP</given-names></name><name><surname>Swaak</surname><given-names>AJ</given-names></name></person-group>. <article-title>Cognitive and emotional disturbances in systemic lupus erythematosus</article-title>. <source>Psychother Psychosom</source> <year>1991</year>; <volume>55</volume>: <fpage>126</fpage>–<lpage>131</lpage>. <comment>. PMID: 1 891 558</comment>.</citation></ref>
<ref id="bibr36-0961203312468963"><label>36</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ferstl</surname><given-names>R</given-names></name><name><surname>Niemann</surname><given-names>T</given-names></name><name><surname>Biehl</surname><given-names>G</given-names></name><name><surname>Hinrichsen</surname><given-names>H</given-names></name><name><surname>Kirch</surname><given-names>W</given-names></name></person-group>. <article-title>Neuropsychological impairment in auto-immune disease</article-title>. <source>Eur J Clin Invest</source> <year>1992</year>; <volume>22</volume>(<supplement>Suppl 1</supplement>): <fpage>16</fpage>–<lpage>20</lpage>. <comment>. PMID: 1 459 180</comment>.</citation></ref>
<ref id="bibr37-0961203312468963"><label>37</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Fisk</surname><given-names>JD</given-names></name><name><surname>Eastwood</surname><given-names>B</given-names></name><name><surname>Sherwood</surname><given-names>G</given-names></name><name><surname>Hanly</surname><given-names>JG</given-names></name></person-group>. <article-title>Patterns of cognitive impairment in patients with systemic lupus erythematosus</article-title>. <source>Br J Rheumatol</source> <year>1993</year>; <volume>32</volume>: <fpage>458</fpage>–<lpage>462</lpage>. <comment>. PMID: 8 508 281</comment>.</citation></ref>
<ref id="bibr38-0961203312468963"><label>38</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hanly</surname><given-names>JG</given-names></name><name><surname>Fisk</surname><given-names>JD</given-names></name><name><surname>Sherwood</surname><given-names>G</given-names></name><name><surname>Jones</surname><given-names>E</given-names></name><name><surname>Jones</surname><given-names>JV</given-names></name><name><surname>Eastwood</surname><given-names>B</given-names></name></person-group>. <article-title>Cognitive impairment in patients with systemic lupus erythematosus</article-title>. <source>J Rheumatol</source> <year>1992</year>; <volume>19</volume>: <fpage>562</fpage>–<lpage>567</lpage>. <comment>. PMID: 1 593 578</comment>.</citation></ref>
<ref id="bibr39-0961203312468963"><label>39</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hanly</surname><given-names>JG</given-names></name><name><surname>Walsh</surname><given-names>NM</given-names></name><name><surname>Fisk</surname><given-names>JD</given-names></name><etal/></person-group>. <article-title>Cognitive impairment and autoantibodies in systemic lupus erythematosus</article-title>. <source>Br J Rheumatol</source> <year>1993</year>; <volume>32</volume>: <fpage>291</fpage>–<lpage>296</lpage>. <comment>. PMID: 8 461 922</comment>.</citation></ref>
<ref id="bibr40-0961203312468963"><label>40</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Papero</surname><given-names>PH</given-names></name><name><surname>Bluestein</surname><given-names>HG</given-names></name><name><surname>White</surname><given-names>P</given-names></name><name><surname>Lipnick</surname><given-names>RN</given-names></name></person-group>. <article-title>Neuropsychologic deficits and antineuronal antibodies in pediatric systemic lupus erythematosus</article-title>. <source>Clin Exp Rheumatol</source> <year>1990</year>; <volume>8</volume>: <fpage>417</fpage>–<lpage>424</lpage>.</citation></ref>
<ref id="bibr41-0961203312468963"><label>41</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sailer</surname><given-names>M</given-names></name><name><surname>Burchert</surname><given-names>W</given-names></name><name><surname>Ehrenheim</surname><given-names>C</given-names></name><etal/></person-group>. <article-title>Positron emission tomography and magnetic resonance imaging for cerebral involvement in patients with systemic lupus erythematosus</article-title>. <source>J Neurology</source> <year>1997</year>; <volume>244</volume>: <fpage>186</fpage>–<lpage>193</lpage>. <comment>. PMID: 9 050 960</comment>.</citation></ref>
<ref id="bibr42-0961203312468963"><label>42</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Tomietto</surname><given-names>P</given-names></name><name><surname>Annese</surname><given-names>V</given-names></name><name><surname>D'Agostini</surname><given-names>S</given-names></name><etal/></person-group>. <article-title>General and specific factors associated with severity of cognitive impairment in systemic lupus erythematosus</article-title>. <source>Arthritis Rheum</source> <year>2007</year>; <volume>57</volume>: <fpage>1461</fpage>–<lpage>1472</lpage>. <comment>. PMID: 18 050 188</comment>.</citation></ref>
<ref id="bibr43-0961203312468963"><label>43</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Filley</surname><given-names>CM</given-names></name><name><surname>Kozora</surname><given-names>E</given-names></name><name><surname>Brown</surname><given-names>MS</given-names></name><etal/></person-group>. <article-title>White matter microstructure and cognition in non-neuropsychiatric systemic lupus erythematosus</article-title>. <source>Cogn Behav Neurol</source> <year>2009</year>; <volume>22</volume>: <fpage>38</fpage>–<lpage>44</lpage>. <comment>. PMID: 19 372 769</comment>.</citation></ref>
<ref id="bibr44-0961203312468963"><label>44</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Erkan</surname><given-names>D</given-names></name><name><surname>Kozora</surname><given-names>E</given-names></name><name><surname>Lockshin</surname><given-names>MD</given-names></name></person-group>. <article-title>Cognitive dysfunction and white matter abnormalities in antiphospholipid syndrome</article-title>. <source>Pathophysiology</source> <year>2011</year>; <volume>18</volume>: <fpage>93</fpage>–<lpage>102</lpage>.</citation></ref>
<ref id="bibr45-0961203312468963"><label>45</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kozora</surname><given-names>E</given-names></name><name><surname>Brown</surname><given-names>MS</given-names></name><name><surname>Filley</surname><given-names>CM</given-names></name><etal/></person-group>. <article-title>Memory impairment associated with neurometabolic abnormalities of the hippocampus in patients with non-neuropsychiatric systemic lupus erythematosus</article-title>. <source>Lupus</source> <year>2011</year>; <volume>20</volume>: <fpage>598</fpage>–<lpage>606</lpage>.</citation></ref>
<ref id="bibr46-0961203312468963"><label>46</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Katz</surname><given-names>P</given-names></name><name><surname>Julian</surname><given-names>L</given-names></name><name><surname>Tonner</surname><given-names>MC</given-names></name><etal/></person-group>. <article-title>Physical activity, obesity, and cognitive impairment among women with systemic lupus erythematosus</article-title>. <source>Arthritis Care Res (Hoboken)</source> <year>2012</year>; <volume>64</volume>: <fpage>502</fpage>–<lpage>510</lpage>.</citation></ref>
</ref-list>
</back>
</article>